Adoption of evidence-based novel therapies in the treatment of gastric cancer: A national observational study

Ali A. Mokdad, Amna Ali, Adam C. Yopp, Patricio M. Polanco, Ibrahim Nassour, John C. Mansour, Michael A. Choti, Rebecca M. Minter, Sam C. Wang, Matthew R. Porembka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: The adoption of novel and effective gastric cancer therapies into general clinical practice has crucial implications for patient outcomes. The current study explored trends in treatment use and overall survival in patients with gastric cancer in the United States. METHODS: Patients with adenocarcinoma of the gastric cardia and noncardia were identified in the National Cancer Data Base between 2006 and 2014. Tumor stages were divided into early (IA), locally advanced (IB-IIIC), and metastatic (IV) stage. Treatment use was examined according to tumor stage and location. Time trend analyses of treatment use and overall survival were conducted. RESULTS: A total of 89,098 patients with gastric adenocarcinoma were identified. In those with early-stage cancer, endoscopic treatment increased over time in patients with cardia and noncardia disease. In patients with locally advanced cardia disease, preoperative therapy use increased over time (2013-2014 [vs 2006-2008]: odds ratio [OR], 3.09; 95% confidence interval [95% CI], 2.80-3.41). In patients with locally advanced noncardia disease, the use of preoperative therapy also increased (2013-2014: OR, 3.32; 95% CI, 2.88-3.82) as did the use of perioperative therapy (2013-2014: OR, 4.21; 95% CI, 3.52-5.03) in lieu of postoperative treatment (2013-2014: OR, 0.66; 95% CI, 0.60-0.71). In patients with metastatic disease, approximately 34% of patients with cardia and 40% of patients with noncardia cancer did not receive treatment. Stage-specific and location-specific overall survival was found to improve over the study period. CONCLUSIONS: Practice patterns for the treatment of gastric cancer in the United States reflect the increased adoption of evidence-based therapies, including endoscopic resection of early-stage cancer and preoperative therapy for patients with locally advanced disease. Treatment for metastatic disease remains markedly underused. Cancer 2018;124:1122-31.

Original languageEnglish (US)
Pages (from-to)1122-1131
Number of pages10
JournalCancer
Volume124
Issue number6
DOIs
StatePublished - Mar 15 2018

Fingerprint

Stomach Neoplasms
Observational Studies
Cardia
Therapeutics
Odds Ratio
Neoplasms
Confidence Intervals
Survival
Stomach
Adenocarcinoma
General Practice
Databases

Keywords

  • stage
  • stomach neoplasm
  • survival
  • treatment
  • trend

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Adoption of evidence-based novel therapies in the treatment of gastric cancer : A national observational study. / Mokdad, Ali A.; Ali, Amna; Yopp, Adam C.; Polanco, Patricio M.; Nassour, Ibrahim; Mansour, John C.; Choti, Michael A.; Minter, Rebecca M.; Wang, Sam C.; Porembka, Matthew R.

In: Cancer, Vol. 124, No. 6, 15.03.2018, p. 1122-1131.

Research output: Contribution to journalArticle

@article{b1aa752df45547c299f72ccc79feafec,
title = "Adoption of evidence-based novel therapies in the treatment of gastric cancer: A national observational study",
abstract = "BACKGROUND: The adoption of novel and effective gastric cancer therapies into general clinical practice has crucial implications for patient outcomes. The current study explored trends in treatment use and overall survival in patients with gastric cancer in the United States. METHODS: Patients with adenocarcinoma of the gastric cardia and noncardia were identified in the National Cancer Data Base between 2006 and 2014. Tumor stages were divided into early (IA), locally advanced (IB-IIIC), and metastatic (IV) stage. Treatment use was examined according to tumor stage and location. Time trend analyses of treatment use and overall survival were conducted. RESULTS: A total of 89,098 patients with gastric adenocarcinoma were identified. In those with early-stage cancer, endoscopic treatment increased over time in patients with cardia and noncardia disease. In patients with locally advanced cardia disease, preoperative therapy use increased over time (2013-2014 [vs 2006-2008]: odds ratio [OR], 3.09; 95{\%} confidence interval [95{\%} CI], 2.80-3.41). In patients with locally advanced noncardia disease, the use of preoperative therapy also increased (2013-2014: OR, 3.32; 95{\%} CI, 2.88-3.82) as did the use of perioperative therapy (2013-2014: OR, 4.21; 95{\%} CI, 3.52-5.03) in lieu of postoperative treatment (2013-2014: OR, 0.66; 95{\%} CI, 0.60-0.71). In patients with metastatic disease, approximately 34{\%} of patients with cardia and 40{\%} of patients with noncardia cancer did not receive treatment. Stage-specific and location-specific overall survival was found to improve over the study period. CONCLUSIONS: Practice patterns for the treatment of gastric cancer in the United States reflect the increased adoption of evidence-based therapies, including endoscopic resection of early-stage cancer and preoperative therapy for patients with locally advanced disease. Treatment for metastatic disease remains markedly underused. Cancer 2018;124:1122-31.",
keywords = "stage, stomach neoplasm, survival, treatment, trend",
author = "Mokdad, {Ali A.} and Amna Ali and Yopp, {Adam C.} and Polanco, {Patricio M.} and Ibrahim Nassour and Mansour, {John C.} and Choti, {Michael A.} and Minter, {Rebecca M.} and Wang, {Sam C.} and Porembka, {Matthew R.}",
year = "2018",
month = "3",
day = "15",
doi = "10.1002/cncr.31179",
language = "English (US)",
volume = "124",
pages = "1122--1131",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Adoption of evidence-based novel therapies in the treatment of gastric cancer

T2 - A national observational study

AU - Mokdad, Ali A.

AU - Ali, Amna

AU - Yopp, Adam C.

AU - Polanco, Patricio M.

AU - Nassour, Ibrahim

AU - Mansour, John C.

AU - Choti, Michael A.

AU - Minter, Rebecca M.

AU - Wang, Sam C.

AU - Porembka, Matthew R.

PY - 2018/3/15

Y1 - 2018/3/15

N2 - BACKGROUND: The adoption of novel and effective gastric cancer therapies into general clinical practice has crucial implications for patient outcomes. The current study explored trends in treatment use and overall survival in patients with gastric cancer in the United States. METHODS: Patients with adenocarcinoma of the gastric cardia and noncardia were identified in the National Cancer Data Base between 2006 and 2014. Tumor stages were divided into early (IA), locally advanced (IB-IIIC), and metastatic (IV) stage. Treatment use was examined according to tumor stage and location. Time trend analyses of treatment use and overall survival were conducted. RESULTS: A total of 89,098 patients with gastric adenocarcinoma were identified. In those with early-stage cancer, endoscopic treatment increased over time in patients with cardia and noncardia disease. In patients with locally advanced cardia disease, preoperative therapy use increased over time (2013-2014 [vs 2006-2008]: odds ratio [OR], 3.09; 95% confidence interval [95% CI], 2.80-3.41). In patients with locally advanced noncardia disease, the use of preoperative therapy also increased (2013-2014: OR, 3.32; 95% CI, 2.88-3.82) as did the use of perioperative therapy (2013-2014: OR, 4.21; 95% CI, 3.52-5.03) in lieu of postoperative treatment (2013-2014: OR, 0.66; 95% CI, 0.60-0.71). In patients with metastatic disease, approximately 34% of patients with cardia and 40% of patients with noncardia cancer did not receive treatment. Stage-specific and location-specific overall survival was found to improve over the study period. CONCLUSIONS: Practice patterns for the treatment of gastric cancer in the United States reflect the increased adoption of evidence-based therapies, including endoscopic resection of early-stage cancer and preoperative therapy for patients with locally advanced disease. Treatment for metastatic disease remains markedly underused. Cancer 2018;124:1122-31.

AB - BACKGROUND: The adoption of novel and effective gastric cancer therapies into general clinical practice has crucial implications for patient outcomes. The current study explored trends in treatment use and overall survival in patients with gastric cancer in the United States. METHODS: Patients with adenocarcinoma of the gastric cardia and noncardia were identified in the National Cancer Data Base between 2006 and 2014. Tumor stages were divided into early (IA), locally advanced (IB-IIIC), and metastatic (IV) stage. Treatment use was examined according to tumor stage and location. Time trend analyses of treatment use and overall survival were conducted. RESULTS: A total of 89,098 patients with gastric adenocarcinoma were identified. In those with early-stage cancer, endoscopic treatment increased over time in patients with cardia and noncardia disease. In patients with locally advanced cardia disease, preoperative therapy use increased over time (2013-2014 [vs 2006-2008]: odds ratio [OR], 3.09; 95% confidence interval [95% CI], 2.80-3.41). In patients with locally advanced noncardia disease, the use of preoperative therapy also increased (2013-2014: OR, 3.32; 95% CI, 2.88-3.82) as did the use of perioperative therapy (2013-2014: OR, 4.21; 95% CI, 3.52-5.03) in lieu of postoperative treatment (2013-2014: OR, 0.66; 95% CI, 0.60-0.71). In patients with metastatic disease, approximately 34% of patients with cardia and 40% of patients with noncardia cancer did not receive treatment. Stage-specific and location-specific overall survival was found to improve over the study period. CONCLUSIONS: Practice patterns for the treatment of gastric cancer in the United States reflect the increased adoption of evidence-based therapies, including endoscopic resection of early-stage cancer and preoperative therapy for patients with locally advanced disease. Treatment for metastatic disease remains markedly underused. Cancer 2018;124:1122-31.

KW - stage

KW - stomach neoplasm

KW - survival

KW - treatment

KW - trend

UR - http://www.scopus.com/inward/record.url?scp=85043332506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043332506&partnerID=8YFLogxK

U2 - 10.1002/cncr.31179

DO - 10.1002/cncr.31179

M3 - Article

C2 - 29211302

AN - SCOPUS:85043332506

VL - 124

SP - 1122

EP - 1131

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -